Compare Jones Lang LaSalle Inc (JLL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| JLL | XBI | |
|---|---|---|
Market Cap | $13.95B | $10.11B |
Volume | 457,462 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $392.79 | $169.55 |
52-Week Low | $280.16 | $104.99 |
Typical Hold Time | 71 Days | 38 Days |
Enterprise Value | $16.71B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $299.87, up 1.08% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $5.26 exceeding the $4.56 estimate. Revenue grew to $26.12B in 2025, and net income margin improved to 3.64%. Recent news highlights acquisitions and financing deals, such as the $406M Trammell Crow Center financing announced on September 24, 2026.
The outlook is positive, supported by analyst consensus price target of $450.50 and 58.33% buy ratings. Key opportunities include growth in data center operations and proprietary platforms, while risks involve real estate market volatility and competitive pressures. The stock offers value with a P/E of 14.54 and P/S of 0.53, but investors should monitor debt levels and economic cycles.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
